Ask AI
ProCE Banner Activity

Frontline Management of Transplant-Ineligible Multiple Myeloma: Optimizing Therapy, Supportive Care, and Patient Outcomes

Slideset

Download these slides to learn how to integrate anti-CD38–based treatment regimens for patients with multiple myeloma who have deferred or are ineligible for transplant.

Released: July 31, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with high-risk smoldering or newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recommend individualized treatment strategies leveraging anti-CD38–based quadruplets for appropriate patients with newly diagnosed symptomatic MM based on the latest clinical evidence, expert recommendations, and patient/disease factors

  • Apply pharmacist-led strategies to mitigate and manage adverse events related to anti-CD38–based treatments for MM